Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : Drugmaker will donate meds for US push to end HIV epidemic

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/09/2019 | 05:47pm EDT

WASHINGTONThe Health and Human Services Department says a major drugmaker has agreed to donate medications that reduce the risk of HIV transmission for up to 200,000 people a year in support of the government's plan to end the epidemic in the U.S.

The pledge by California-based Gilead Sciences may last up to 11 years, said HHS Secretary Alex Azar. Gilead will donate its Truvada prevention pill until a second-generation version becomes available.

The Trump administration has set a goal of ending the HIV epidemic in the U.S. within 10 years.

Carl Schmid of the AIDS Institute called the donation "a really significant step," saying it will make the drug available to uninsured people. It lists for more than $20,000 per patient, per year.

HIV is the virus that causes AIDS.

© 2019 The Canadian Press. All rights reserved., source Canadian Press DataFile

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
06/14GILEAD SCIENCES : A cure for HIV? Gilead VP in Israel for Pride Parade says one ..
AQ
06/14GILEAD SCIENCES : AbCellera Announces Therapeutic Antibody Discovery Collaborati..
AQ
06/13Health Care Down on Cyclical Bias -- Health Care Roundup
DJ
06/13GILEAD SCIENCES : Ex-dividend day for
FA
06/11GILEAD SCIENCES : Statement on U.S. Preventive Services Task Force 'A' Recommend..
PU
06/04GILEAD SCIENCES : Kite Announces New Yescarta Data from ZUMA-1
AQ
06/03GILEAD SCIENCES : Company - Kite and Humanigen Announce Clinical Collaboration t..
AQ
06/03GILEAD SCIENCES : Kite Announces New Yescarta® Data From ZUMA-1
BU
06/03GILEAD SCIENCES : Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Ad..
AQ
06/01GILEAD SCIENCES : Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Ad..
BU
More news
Financials ($)
Sales 2019 22 048 M
EBIT 2019 11 439 M
Net income 2019 6 954 M
Debt 2019 5 969 M
Yield 2019 3,87%
P/E ratio 2019 12,02
P/E ratio 2020 11,86
EV / Sales 2019 4,04x
EV / Sales 2020 3,66x
Capitalization 83 096 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 80,0 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES6.09%80 909
VERTEX PHARMACEUTICALS2.72%42 680
REGENERON PHARMACEUTICALS-18.28%32 744
GENMAB10.45%10 857
SAREPTA THERAPEUTICS INC9.57%8 523
NEUROCRINE BIOSCIENCES, INC.17.52%7 500